<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VENLAFAXINE <img border="0" src="../images/pr.gif"/></span><br/>(ven-la-fax'een)<br/><span class="topboxtradename">Effexor, </span><span class="topboxtradename">Effexor XR<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">antidepressant</span>; <span class="classification">serotonin norepinephrine reuptake inhibitor (snri)</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg tablets; 37.5 mg, 75 mg, 150 mg sustained-release capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Selectively inhibits neuronal uptake of serotonin, norepinephrine, and dopamine in decreasing order of potency. A bicyclic
         "second-generation" antidepressant, drug is chemically unrelated to tricyclic, tetracyclic, or other antidepressants.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antidepressant effect is presumed to be linked to its inhibition of CNS presynaptic neuronal uptake of serotonin. Drug does
         not cause anticholinergic, sedative, or cardiovascular effects.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Depression, generalized anxiety disorder; social anxiety disorder.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Obsessive-compulsive disorder.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to venlafaxine, or other SNRI drugs; concurrent administration with MAO inhibitors; abrupt discontinuation;
         neonates; pregnancy (category C), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal and hepatic impairment, renal failure; anorexia nervosa, history of mania, suicidal ideations; elevated intraocular
         pressure, acute closed-angle glaucoma; cardiac disorders, recent MI, heart failure; hypertension; hyperthyroidism; concomitant
         administration with CNS drugs, CNS depression; history of seizures or seizure disorders; older adults. Safety in children
         
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Depression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 25125 mg t.i.d.<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with lower doses in older adults<br/><br/><span class="indicationtitle">Anxiety</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 37.5 mg sustained-release q.d. and increase to 75225 mg sustained-release per day<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 1070 mL/min: reduce total daily dose by 2550%; <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food. Sustained-release capsules must be swallowed whole, must not be opened or chewed.</li>
<li>Dosage increments of up to 75 mg/d are usually made at 4 d or longer intervals.</li>
<li>Allow 14 d interval after discontinuing an MAO inhibitor before starting venlafaxine.</li>
<li>Do not abruptly withdraw drug after 1 wk or more of therapy.</li>
<li>Store at room temperature, 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> CV:</span> <span class="speceff-common">Increased blood pressure and heart rate,</span> palpitations. <span class="typehead">CNS:</span> <span class="speceff-common">Dizziness,</span> fatigue, headache, anxiety, insomnia, <span class="speceff-common">somnolence</span>. <span class="typehead">Endocrine:</span> Small but statistically significant increase in serum cholesterol, weight loss (approximately 3 lb). <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, dry mouth,</span> constipation. <span class="typehead">Urogenital:</span> Sexual dysfunction, erectile failure, delayed orgasm, anorgasmia, impotence, abnormal ejaculation. <span class="typehead">Special Senses:</span> Blurred vision. <span class="typehead">Body as a Whole:</span> <span class="speceff-common">Sweating,</span> asthenia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Cimetidine,</b> <span class="classification">mao inhibitors</span>, <b>desipramine,</b> <b>haloperidol</b> may increase venlafaxine levels and toxicity. Should not use in combination with <span class="classification">mao inhibitors</span>: do not start until &gt;14 d after stopping <span class="classification">mao inhibitor</span>; do not start <span class="classification">mao inhibitor</span> until 7 d after stopping venlafaxine. <b>Trazodone</b> may lead to <b>serotonin</b> syndrome. <span class="typehead">Herbal:</span> <b>St. John's wort</b> may cause <b>serotonin</b> syndrome. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from GI tract. <span class="typehead">Onset:</span> 2 wk. <span class="typehead">Peak:</span> Venlafaxine 12 h; metabolite 34 h. <span class="typehead">Duration:</span> Approximately 30% protein bound, but extensively tissue bound. <span class="typehead">Metabolism:</span> Undergoes substantial first-pass metabolism to its major active metabolite, <i>O</i>-desmethylvenlafaxine, with similar activity to venlafaxine. <span class="typehead">Elimination:</span> Approximately 60% excreted in urine as parent compound and metabolites. <span class="typehead">Half-Life:</span> Venlafaxine 34 h, <i>O</i>-desmethylvenlafaxine 10 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for worsening of depression or emergence of suicidal ideation.</li>
<li>Monitor cardiovascular status periodically with measurements of HR and BP.</li>
<li>Lab tests: Periodic lipid profile.</li>
<li>Monitor neurologic status and report excessive anxiety, nervousness, and insomnia.</li>
<li>Monitor weight periodically and report excess weight loss.</li>
<li>Assess safety, as dizziness and sedation are common.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware of potential adverse effects and notify physician of those that are bothersome.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Avoid using alcohol while on venlafaxine.</li>
<li>Do not use herbal medications without consulting physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>